Vanguard Group’s Apexigen, Inc. Common Stock APGN Stock Holding History

Vanguard Group’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-256,935	Closed	-$110K	–	4592
2023 Q2	$110K	Hold	256,935	–	–	﹤0.01%	4384
2023 Q1	$125K	Hold	256,935	–	–	﹤0.01%	4379
2022 Q4	$175K	Buy	256,935 +380	+0.1%	+$741	﹤0.01%	4329
2022 Q3	$692K	Buy	+256,555	New	+$2.09M	﹤0.01%	4116

Vanguard Group's APGN Position: Q3 2023 in Review

Vanguard Group sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2023, closing a stake of 256,935 shares — an estimated $110K sold.

Vanguard Group first reported a position in APGN in Q3 2022 and held it in 4 quarters. The position peaked at $692K in Q3 2022. 0 funds tracked by Wall St. Rank hold APGN as of Q3 2023.

Vanguard Group reported no remaining Apexigen, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vanguard Group sold 256,935 Apexigen, Inc. Common Stock shares in Q3 2023, an estimated $110K.
Vanguard Group first reported a position in Apexigen, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Vanguard Group's Apexigen, Inc. Common Stock position peaked at $692K in Q3 2022.
0 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.